Glenmark bags USFDA nod for Clindamycin Phosphate Foam

Mumbai: Drugmaker, Glenmark Pharmaceuticals Ltd., announced that the company has received final approval from the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1%.

The product is a generic version of Evoclin Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately $12.0 million*.

Glenmark's current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA.

"In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio," the company said in its recent release.

Glenmark had earlier received tentative approval from the United States Food & Drug Administration (USFDA) for Nintedanib Capsules, 100 mg and 150 mg.

Read also: Glenmark bags USFDA nod for Nintedanib Capsules

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.